Amneal Pharmaceuticals (AMRX) Tops Q2 EPS by 2c, provides guidance

Amneal Pharmaceuticals (NASDAQ: AMRX) reported Q2 EPS of $0.16, $0.02 better than the analyst estimate of $0.14. Revenue for the quarter came in at $702 million versus the consensus estimate of $658.63 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2024 EPS of $0.53-$0.63, versus the consensus of $0.61. Amneal Pharmaceuticals sees FY2024 revenue of $2.55-2.65 billion, versus the consensus of $2.644 billion.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.

You May Also Be Interested In

• Gulfport Energy and Mobility Global to join S&P SmallCap 600
• Deutsche Bank Upgrades Softbank Group Corp. (9984:JP) (SFTBY) to Buy
• Deutsche Bank Downgrades Synaptics (SYNA) to Hold